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Blood culture (BC) is the ‘gold standard’ for the 
detec tion of micro-organisms in the bloodstream. 
The 2010 South African (SA) guideline for the 
optimal use of BCs aims to optimise BC yield and 
reduce contamination. [1] There are approximately 
20 000 deaths per day from sepsis worldwide,[2] and BC plays an 
integral role in identifying bacter aemia and guiding diagnostic and 
therapeutic choices. It is also one of the cornerstones of antimicrobial 
stewardship, which has reduced the overuse of antibiotics and costs 
in hospitalised patients.[3]
The interpretation of BC results may be complicated by the recovery 
of potential contaminants. The Clinical and Laboratory Standards 
Institute (CLSI)’s benchmark for the maximum acceptable percentage 
of contaminated BCs is 3%.[4] Contaminated BCs are associated with 
additional laboratory testing, unnecessary prescription of antibiotics 
and increased patient charges.[5] A recent audit of BCs among adult 
patients at GF Jooste Hospital in Cape Town, SA, reported high 
rates of contamination by coagulase-negative staphylococci (CoNS) 
ranging from 4.6% to 9.3% per year.[6]
To our knowledge, there has not been a comprehensive audit of BC 
collection practices in SA since the publication of the SA guideline.[1]
Objectives
To evaluate compliance with the SA guideline[1] for the optimal 
collection of BCs and to determine the institutional BC contamination 
rate at a district hospital in Cape Town.
Methods
Study design
We conducted an audit of compliance with 22 BC standards (Table 1) 
derived from the national guideline.[1] Clinical and laboratory data 
were extracted over a 3-month period (1 November 2013 - 31 January 
2014). All patient data were anonymised. The study was approved 
by the Research Ethics Committee of Stellenbosch University, Cape 
Town (Protocol REC S12/09/248).
Setting and patient population
The audit was conducted at a 282-bed district hospital in Cape 
Town. The hospital is situated 3.5 km from the National Health 
Laboratory Service (NHLS) microbiology laboratory, located at 
Tygerberg Hospital. A courier service collects specimens from the 
hospital and delivers them to the laboratory 12 times a day on week 
days and 8 times a day over weekends. All adult inpatients (≥13 
years) from whom BCs were collected were eligible for inclusion. 
Mycobacterial BCs were excluded because the mycobacterial BC 
instrument used was different from that used for routine BCs.
Definitions
A BC was defined as a sample of blood obtained from a single 
venepuncture site, irrespective of whether the blood was inoculated 
into one or multiple BC bottles.
A BC was considered to be contaminated if one or more of the 
following skin flora organisms were identified in only one of a series 
of BCs: CoNS, Corynebacterium spp., viridans group streptococci, 
Micrococcus spp., Bacillus spp., and Propionibacterium spp.[7] This 
included BCs with a potential pathogen, in addition to a contaminant. 
Polymicrobic BCs with more than one contaminant species were 
considered as being a single contaminated BC.[8] If any of the 
abovementioned skin flora organisms were cultured from a solitary 
blood culture (SBC) (single BC within a 24-hour period), the medical 
records and medication charts were retrospectively reviewed. BCs were 
classified as clinically significant if antibiotic treatment was initiated or 
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continued as a therapeutic response to the BC result, an intravascular 
line was removed or replaced as a therapeutic response to the BC result, 
or the BC result was associated with an expected clinical condition 
(e.g. graft sepsis, shunt sepsis or endocarditis). All positive BCs with a 
recognised pathogen were considered to be clinically significant.
Needle-to-incubator transport time was defined as the time differ-
ence between BC collection and insertion of BC bottles into the BC 
instrument. Insertion on the day of sample collection was defined 
as same-day incubation, and insertion on a different day as delayed 
incubation.
The institutional BC contamination rate was defined as the 
number of contaminated BCs processed during the study period, 
divided by the total number of BCs performed during that period.[8]
Data sources
• Clinical and laboratory data were extracted from clinical case 
notes, laboratory request forms, BC bottles, medication charts and 
the laboratory information system (LIS).
• BC bottle volume was determined by subtracting the post-filling 
weight from the standard pre-filled weight. One mL of blood weighs 
approximately 1 g. The manufacturer (bioMérieux) recommends that 
a sample volume of 8 - 10 mL blood be provided per bottle and that 
the maximum sample volume should not exceed 10 mL per bottle.
• Needle-to-incubator transport time was calculated using the date 
and time of BC collection documented on the laboratory request 
form and the times available on the LIS.
• A clinician questionnaire was designed to evaluate standards relating 
to obtaining informed consent, BC ordering practices, skin and bottle-
top antisepsis, BC collection technique, and storage of BC bottles.
Data evaluation (standards numbered as per Table 1)
• Standard 1 was evaluated by reviewing the working diagnosis in 
the clinical case notes at the time of BC collection.
• Standards 2, 4 - 6, 8 - 14 and 21 were evaluated by a clinician 
questionnaire. Selected clinician responses were ranked as follows: 
always (>95%), usually (50 - 95%), sometimes (5 - 50%), rarely 
(<5%), and uncertain.
• Standard 3 was evaluated by reviewing laboratory request forms, 
medication charts and the clinician questionnaire.
• Standard 7 was evaluated by reviewing the site of BC collection as 
indicated on the laboratory request forms.
• Standards 15 - 20 and 22 were evaluated by reviewing laboratory 
request forms, BC bottles, clinical case notes and the LIS.
Laboratory procedures
BC bottles were transported to the laboratory and incubated either 
until they flagged positive, or for 5 days (or longer if extended 
incubation was required) in the BacT/Alert (bioMérieux, SA) BC 
system. Broths from positive bottles were Gram-stained and further 
identified using standard techniques.[9]
Statistical analysis
Conventional descriptive methods were used for data analysis. 
Percentages were reported for categorical variables and median 
and interquartile ranges (IQRs) for continuous variables. Selected 
Table 1. Blood culture standards
S1 BCs should be drawn if there is a clinical suspicion of a 
bloodstream infection.
S2 Informed consent should be obtained prior to performing a BC.
S3 BCs should be collected prior to administration of antibiotics.
S4 Hand washing should be performed prior to performing a BC.
S5 Hands should be disinfected prior to performing a BC.
S6 Sterile gloves should be used when performing a BC.
S7 BCs should be drawn from peripheral sites.
S8 BCs should be collected from separate venepuncture sites.
S9 Puncture site should be cleaned using appropriate disinfectant.
S10 Skin disinfectant should be allowed time to dry before 
inserting the needle.
S11 BC bottle tops should be disinfected prior to inoculation.
S12 Bottle-top disinfectant should be allowed to dry prior to 
inoculation.
S13 Needles should not be exchanged between BC collection and 
inoculation of BC bottles.
S14 BC bottles should be inoculated first, if blood is collected for 
other tests.
S15 Minimum of 2 and maximum of 3 BCs should be drawn 
within 24 hours. 
S16 Aerobic BC bottles should be used in a resource-limited 
setting.
S17 Minimum of 20 mL of blood (10 mL per bottle) should be 
obtained for each BC.
S18 BC bottles should be correctly labelled.
S19 Laboratory request form should include patient identifiers, 
site, date and time of collection, clinical information regarding 
suspected diagnosis, and contact details of requesting doctor. 
S20 BC collection should be documented in the clinical notes.
S21 BC bottles should be left at room temperature if there is a 
delay in transporting them to the laboratory.
S22 BC bottles should be delivered to the laboratory as soon as 
possible.
Table 2. Micro-organisms recovered from blood cultures*
Isolates, n
Pathogens
Enterobacteriaceae 13
Staphylococcus aureus 8
Streptococcus pneumoniae 6
Pseudomonas aeruginosa 5
Cryptococcus neoformans 2
Staphylococcus hominis† 2
Erysipelothrix rhusiopathiae 1
Streptococcus anginosus 1
Contaminants
Coagulase-negative Staphylococcus spp. 11
Bacillus spp. 4
Viridans group streptococci 3
Corynebacterium spp. 1
Micrococcus spp. 1
*Total of 425 blood cultures with 58 isolates.
†Isolate was cultured from two separate blood cultures in a patient with vascular graft sepsis.
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categorical data were evaluated using the χ2 test, and a p-value 
of <0.05 was regarded as statistically significant.
Results
We reviewed 425 BCs (531 BC bottles) collected from 353 patients 
in different wards over a 3-month period. Table 2 shows the 
organisms recovered from BCs. More than one bacterial species was 
demonstrated in 1.2% (5/425) of BCs. The BC contamination rate 
was 4.5% (19/425) (Table 3).
The clinician questionnaire response rate was 70.0% (30/43). 
Compliance with standards relating to obtaining informed consent, 
skin and bottle-top antisepsis and BC collection technique was 
variable (Fig. 1). Forty-eight percent (13/27) of doctors reported 
using only chlorhexidine for skin antisepsis; 26.0% (7/27) reported 
using chlorhexidine and 70% alcohol; 18.5% (5/27) reported using 
only 70% alcohol; 3.7% (1/27) reported using both chlorhexidine and 
povidone; and 3.7% (1/27) reported that they did not know which 
skin disinfectant to use.
The indications for performing BCs were diverse, with sepsis and 
fever being the most common indications (Table 4).
We were able to determine the temporal relationship between 
BC collection and antibiotic exposure for 81.7% (343/425) of 
BCs. Of these cultures, 53.6% (184/343) were collected after 
in-hospital exposure to antibiotics in the preceding 24 hours. 
The overall yield of BCs collected after in-hospital antibiotic 
exposure was 7.6% (14/184) and that of those collected with no 
prior in-hospital antibiotic exposure was 15.1% (24/159) (odds 
ratio (OR) 0.46; 95% confidence interval (CI) 0.23 - 0.93; p=0.04). 
However, the yield of pathogens in BCs collected after antibiotic 
exposure was 4.9% (9/184) compared with 7.5% (12/159) for 
those cultures with no prior antibiotic exposure (OR 0.63; 95% 
CI 0.26 - 1.54; p=0.3).
The site of BC collection was indicated on 0.7% (3/425) of labora-
tory request forms. Only one request form indicated that the BC was 
drawn from a central venous catheter (CVC).
Table 3. Total number of, and proportion of, blood culture 
contaminants expressed in terms of number of blood cultures 
and number of blood culture bottles
Blood cultures 
(N=425)
n (%)
Blood culture 
bottles (N=531)
n (%)
Positive blood cultures 53 (12.5) 64 (12.1)
Significant positives 34 (8.0) 43 (8.1)
Contaminants 19 (4.5) 21 (4.0)
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Fig. 1. Standards evaluated and ranked by clinician questionnaire. (*S = standard.)
Table 4. Indications for blood culture*
Indication Frequency %
Sepsis 110 25.9
Fever 78 18.4
Pneumonia 50 11.8
Urinary tract infection 15 3.5
Skin and soft-tissue infection 14 3.3
Meningitis 12 2.8
Diarrhoea 8 1.9
Delirium 6 1.4
Endocarditis 6 1.4
Unclear† 70 16.5
Miscellaneous 55 12.9
*Total of 425 blood cultures from 353 patients.
†Clinical diagnoses were not indicated, no clinical entries could be found, or clinical folder 
could not be located.
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Seventy-five percent (318/425) of BCs comprised a single BC bottle, 
24.7% (105/425) two bottles, and 0.2% (1/425) three bottles. The 
majority (96.9%, 342/353) of patients had a single BC in a 24-hour 
period. Only 3.1% (11/353) of patients had two BCs and no patients 
had three or more BCs within a 24-hour period. Eighty-six percent 
(457/531) of all BC bottles received were aerobic bottles. Thirty-
three percent (175/531) of BC bottles contained a fill volume of 
8 - 10 mL, 46.0% (245/531) contained <8 mL, and 21.0% (111/531) 
contained >10 mL. Only 7.8% (33/425) of BCs collected had a 
blood volume of at least 20 mL. Although the pathogen yield from 
BC bottles with a volume of <8 mL (12/245, 4.9%) was lower than 
the yield from BC bottles with the recommended volume (14/175, 
8.0%), this difference was not statistically significant (OR 0.59; 95% 
CI 0.26 - 1.31; p=0.19).
We were unable to trace the clinical folders or clinical entry sheets 
for 7.3% (31/425) of BCs. BC collection was documented in the 
clinical folders for 85.5% (337/394) of BCs. Ninety-three percent 
(395/425) of the request forms contained patient stickers with the 
relevant patient details. The remainder of the forms comprised 
handwritten patient identifiers, all of which contained a minimum 
of three data sets (first name, surname and folder number). All 
laboratory request forms indicated the date of BC collection, but only 
76.2% (324/425) indicated both the date and time. Of all the request 
forms reviewed, 72.5% (308/425) contained clinical information. The 
name of the requesting doctor was provided on 98.4% (418/425) of 
forms, but only 1.2% (5/425) of forms contained clinician contact 
details. All BC bottles were correctly labelled.
Seventy-seven percent (23/30) of clinicians reported leaving BCs 
at room temperature if there was a delay in transporting them to the 
laboratory. However, 23% (7/30) failed to respond to this question. 
The overall median needle-to-incubator transport time was 11 hours 
25 minutes (IQR 7 hours 6 minutes - 16 hours 53 minutes). For same-
day incubation the median needle-to-incubator transport time was 7 
hours 15 minutes (IQR 5 hours 30 minutes - 9 hours 28 minutes), and 
for delayed incubation it was 16 hours 24 minutes (IQR 12 hours 23 
minutes - 22 hours 30 minutes).
Sixty-three percent (19/30) of clinicians indicated that they were 
unaware of the SA guideline[1] and 70.0% (21/30) were unaware of the 
local NHLS specimen collection manual.
Discussion and conclusion
The main findings of our audit related to poor compliance with hand 
hygiene practices, lack of use of sterile gloves and inadequate skin 
and bottle-top antisepsis. This was clearly reflected in the high BC 
contamination rate of 4.5%.
Controversy still exists as to whether sterile gloving should 
routinely be used during BC collection. However, a randomised 
cross-over trial by Kim et al.[10] found that routine use of sterile gloves 
was associated with a reduction in BC contamination.
The SA guideline refers to the use of povidone or alcohol 
solution to disinfect the puncture site.[1] However, a recent systematic 
review and meta-analysis has concluded that alcoholic chlorhexidine 
solutions showed a statistically significant reduction in BC false 
positives compared with aqueous povidone-iodine.[11] Given the 
current available data, we strongly recommend the use of alcoholic 
chlorhexidine for skin disinfection.
The method of applying the skin antiseptic is also important. 
Traditionally, the concentric circle method was required if aqueous 
iodophors were used after the alcohol step to prevent reintroduction 
of contaminants to previously cleansed areas. There are no data 
supporting applying alcoholic disinfectants in an outward concentric 
circle, but vigorous friction is important.[12] If palpation of the vein is 
necessary after skin disinfection, the gloved finger should be cleansed 
with the antiseptic agent and allowed to dry before touching the site.
BC bottle tops are not necessarily sterile, even though they are 
covered with a lid.[13] Cleaning the BC bottle tops with antiseptic prior 
to specimen inoculation decreases contamination.[8]
Other pre-analytical factors that may also have played a role in 
the high BC contamination rate but were not explored in our study 
include whether or not the venepuncture site was repalpated after 
skin antisepsis, patient-related factors (e.g. unco-operative patients 
or difficult anatomy for venepuncture), and ward factors (e.g. high 
staff turnover, inexperienced staff, BC equipment lacking or difficult 
to locate).
Other significant findings of our audit relate to prior administration 
of antibiotics, high number of SBCs, inadequate blood volume and 
prolonged needle-to-incubator transport time. All these factors are 
likely to contribute to the low BC yield of true pathogens found in 
this study.
Recent antibiotic treatment can have a significant impact on the 
BC results by decreasing the sensitivity of the test. BC collection 
before initiation of antimicrobial therapy is recommended as a 
standard of care in international sepsis guidelines.[14]
The number of SBCs was unacceptably high. The SA guideline[1] 
recommends two or more BCs in cases where sepsis is suspected; this 
is supported by the CLSI and the recent international guidelines of 
the Surviving Sepsis Campaign.[4,14] Two previous Q-Probes studies in 
the USA evaluated SBC collections as a pre-analytic quality indicator 
of BC practice.[15] Of 289  572 BCs, the median proportion of SBCs 
per institution was 10.1%. These studies found that one of the most 
common reasons for not performing a second culture in adults was 
that the doctor believed that one culture was sufficient. However, we 
did not explore the reasons for the high rate of SBCs, but it is probably 
due to a variety of factors including lack of awareness, time pressures, 
lack of BC equipment and difficult anatomy for venepuncture.
A striking feature of our audit was that the vast majority of BC 
bottles were under-filled. The volume of blood tested is the single 
most important variable for the detection of bacteria and yeast from 
BCs.[16] Cockerill et al.[17] demonstrated that yields from 20 mL and 
30 mL of blood were 29.8% and 47.2% greater, respectively, than 
those from 10 mL of blood.. Most bacteraemias in adults have a 
low density of micro-organisms, and 20 - 30 ml per BC is therefore 
recommended.[4] Of all the BC bottles, 21.0% were overfilled. While 
underfilling of BC bottles reduces the sensitivity, overfilling of bottles 
may cause the BC system to flag positive falsely.
BCs received at the Tygerberg NHLS laboratory are not inserted 
into the continuous-monitoring BC instrument on a 24-hour basis; 
those received after 22h00 are not pre-incubated, but stored at room 
temperature until the next day. The extended delay between BC 
collection and incubation is not recommended, as this may delay or 
impede the detection of growth by the BC instrument.[18] However, 
the actual time at which a reduction in BC sensitivity occurs because 
of delays in loading BC bottles is not clearly established. According to 
the UK Standards for Microbiology Investigations, BC bottles should 
be incubated as soon as possible, and within a maximum of 4 hours.[19]
The strengths of our clinical audit were:
• We incorporated both clinical and laboratory data and it was not 
solely laboratory based.
• We attempted to evaluate actual practice and not only the BC 
contamination rate.
• We incorporated all probable skin contaminants and not only 
CoNS when we calculated the BC contamination rate.
• We used the number of BCs (and not the number of BC bottles) to 
calculate the BC contamination rate.
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• When we cultured a probable contaminant from an SBC, we did 
not use only the identification of the organism, but also clini-
cal parameters, before making a judgement about the clinical 
significance of the isolate.
The limitations of our audit were:
• We had limited quantitative data on some of the pre-analytic 
procedures, but they nevertheless provided insight into BC 
collection practices.
• We inferred the indication for BCs from the working clinical 
diagnosis documented in the clinical case notes at the time of BC 
collection, but we did not evaluate specific clinical parameters or 
results from other special investigations.
• When more than one BC bottle was submitted for the same 
patient, using the same laboratory request form, it was counted 
as one BC (unless otherwise specified); this may have led to an 
underestimation of the number of BCs.
• When the site of BC collection was not indicated, it was 
assumed that it was collected from a peripheral site, which may 
have led to an underestimation of the number of BCs collected 
from CVCs.
• We did not audit the availability of equipment (phlebotomy 
materials, BC bottles and sterile BC packs) for performing BCs.
In conclusion, our audit showed a high BC contamination rate. It 
further demonstrated that compliance with most standards at the 
hospital was variable or not met. However, our findings may not be 
generalised to other hospitals and we therefore recommend that each 
institution reviews its own BC practices.
Recommendations for improvement
The audit report was presented to the hospital staff with the following 
recommendations:
• Staff be provided with electronic copies of the SA guideline[1] and 
the NHLS specimen collection manual.
• Pictorial wall charts be posted in each ward, outlining best-practice 
recommendations. 
• BC record stickers be used, indicating the name of the patient and 
doctor, and the date, time, site and indication of BC.
• Weekly antibiotic stewardship rounds be used as a platform to 
educate clinicians regarding best practice when collecting BCs.
• Pre-assembled BC collection packs with procedural checklists be 
used.
• Winged blood collection sets (needle and adaptor) be used.
• A revised laboratory request form be used, with a designated space 
for clinicians to clearly indicate the BC collection.
• Alcoholic chlorhexidine be used as a skin disinfectant in adults.
• Laboratory reports be accompanied by a remark recommending the 
number of BCs and volume of blood, per bottle, for adult patients.
• Pre-analytical factors associated with prolonged needle-to-incu-
bator transport time be investigated.
• BCs be loaded on the BC instrument on a 24-hour basis.
• The audit be repeated after implementation of interventions.
In addition, the regular use of quality indicators (such as blood 
volume, contamination rate, SBC rate, positivity rate, number of BCs 
requested per 1 000 patient-days, needle-to-incubator transport time 
and number of rejected samples) with monitoring and feedback may 
strengthen the above interventions.
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